Abstract
Anti-PD-1/PD-L1 agents have revolutionized the treatment of advanced cancer. However, many patients still do not benefit from these treatments. We sought to evaluate the impact of body mass index on the efficacy of anti-PD-1/PD-L1 drugs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
